PDEX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 18.81% compared to Pro-Dex's net margin of 14.45%. Pro-Dex's return on equity of 29.31% beat Boston Scientific's return on equity of 9.57%.

Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 26.96%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 10.17%. Given that Pro-Dex has higher upside potential than Boston Scientific, analysts believe Pro-Dex is more attractive than Boston Scientific.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $17.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Pro-Dex's net income of $3.3M is lower than Boston Scientific's net income of $674M. Notably, Pro-Dex's price-to-earnings ratio is 15.81x while Boston Scientific's PE ratio is 77.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.31x versus 9.00x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of 18.81% compared to Pro-Dex's net margin of -86.66%. Pro-Dex's return on equity of 29.31% beat Outset Medical's return on equity of -140.06%.

Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 26.96%. On the other hand Outset Medical has an analysts' consensus of $24.00 which suggests that it could grow by 27.73%. Given that Outset Medical has higher upside potential than Pro-Dex, analysts believe Outset Medical is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $17.4M, which are smaller than Outset Medical quarterly revenues of $29.8M. Pro-Dex's net income of $3.3M is higher than Outset Medical's net income of -$25.8M. Notably, Pro-Dex's price-to-earnings ratio is 15.81x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.31x versus 0.71x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 18.81% compared to Pro-Dex's net margin of 6.22%. Pro-Dex's return on equity of 29.31% beat Insulet's return on equity of 36.9%.

Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 26.96%. On the other hand Insulet has an analysts' consensus of $330.19 which suggests that it could grow by 1.09%. Given that Pro-Dex has higher upside potential than Insulet, analysts believe Pro-Dex is more attractive than Insulet.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $17.4M, which are smaller than Insulet quarterly revenues of $569M. Pro-Dex's net income of $3.3M is lower than Insulet's net income of $35.4M. Notably, Pro-Dex's price-to-earnings ratio is 15.81x while Insulet's PE ratio is 58.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.31x versus 10.99x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 18.81% compared to Pro-Dex's net margin of 11.15%. Pro-Dex's return on equity of 29.31% beat Stryker's return on equity of 14.2%.

Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 26.96%. On the other hand Stryker has an analysts' consensus of $420.92 which suggests that it could grow by 9.68%. Given that Pro-Dex has higher upside potential than Stryker, analysts believe Pro-Dex is more attractive than Stryker.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Pro-Dex pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pro-Dex quarterly revenues are $17.4M, which are smaller than Stryker quarterly revenues of $5.9B. Pro-Dex's net income of $3.3M is lower than Stryker's net income of $654M. Notably, Pro-Dex's price-to-earnings ratio is 15.81x while Stryker's PE ratio is 51.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.31x versus 6.38x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.